Consistently, this study analyzed 175 patients with untreated advanced or metastatic NSCLC received PD‐1 blockade plus chemotherapy or chemotherapy and also observed that female patients derived a larger benefit from first‐line PD‐1 blockade in combination with chemotherapy, but not chemotherapy, than male patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.